Drug discovery is long and winding, and riddled with high-cost failure at every turn. A newly unveiled Cambridge startup aims to streamline the process with a platform it’s calling “CRISPRomics” — and it has recruited some top-flight talent to lead the effort.
The two-year-old company — KSQ Therapeutics — just emerged from stealth, announcing a $76 million financing round and a new CEO: Dr. David Meeker, former chief executive of Genzyme. He stepped down from his post at the merged Sanofi-Genzyme (SNY) this past April.
Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!
GET STARTEDWhat is it?
STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.
What's included?
- Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
- Subscriber-only networking events and panel discussions across the country
- Monthly subscriber-only live chats with our reporters and experts in the field
- Discounted tickets to industry events and early-bird access to industry reports
About the Author
